| Project/Area Number |
25861603
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
IMAI TAKAYUKI 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 特任研究員 (80408583)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MATSUURA Kazuto 地方独立法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 特任研究員 (70271947)
TANAKA Nobuyuki 地方独立法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 部長 (60280872)
|
|---|
| Project Period (FY) |
2013-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 癌 / 頭頸部扁平上皮癌 / 癌幹細胞 / 頭頸部癌 / CD271 |
|---|
| Outline of Final Research Achievements |
Cancer stem cells contribute to the malignant phenotypes of a variety of cancers, but markers to identify human head and neck cancer (HNSCC) stem cells remain elusive.Several patient-derived xenograft (PDX) lines were established, and CD271+ population sorted from PDX-derived cells showed an enhanced tumor-initiating capability in immunodeficient mice. Tumors generated from the CD271+ cells contained both CD271- positive and -negative cells, indicating that the population could undergo differentiation. Accordingly, tumor-sheres contained more CD271+ cells than those from the normal in vitro culture condition. After the CDDP treatment, in vivo tumors contained increasing number of CD271+ cells, suggesting CD271+ cells are chemoresistant. Furthermore, using primary specimens, I found that high CD271 expression was correlated with a poor prognosis for patients. Together, the present findings indicate that CD271 is a novel marker for HNSCC stem-like cells and for the prognosis.
|
